Medios AG Logo

Medios AG

Compounding patient-specific therapies and supplying specialty pharma for complex conditions.

ILM1 | F

Overview

Corporate Details

ISIN(s):
DE000A1MMCC8 (+1 more)
LEI:
391200Z7Z09IHDBT2L23
Country:
Germany
Address:
Heidestraße 9, 10557 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medios AG is a leading European specialty pharmaceutical company focused on advancing individualized medicine. The company's core business involves the compounding of patient-specific therapies and the supply of specialty pharma solutions. It serves a diverse client base, including pharmacies, medical specialists, hospitals, and pharmaceutical companies, ensuring reliable access to innovative treatments for complex and chronic conditions. With a strong focus on therapeutic areas such as oncology, neurology, and autoimmune diseases, Medios pioneers the development and distribution of advanced therapies and biotechnological precision medicine. By integrating pharmaceutical supply with specialized compounding services, the company plays a crucial role in making personalized treatments accessible to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-03 09:57
Board/Management Information
Thomas Meier becomes new CEO of Medios AG
English 9.1 KB
2025-10-24 10:45
Declaration of Voting Results & Voting Rights Announcements
English 12.3 KB
2025-09-04 15:00
Declaration of Voting Results & Voting Rights Announcements
English 12.3 KB
2025-08-28 10:15
Declaration of Voting Results & Voting Rights Announcements
English 13.5 KB
2025-08-27 10:37
Declaration of Voting Results & Voting Rights Announcements
English 13.2 KB
2025-08-13 07:37
Earnings Release
Medios accelerates growth in the first half of 2025 and significantly increases…
English 20.0 KB
2025-08-13 00:00
Interim Report
Half-yearly financial report 2025
English 500.4 KB
2025-07-18 11:41
Major Shareholding Notification
English 5.4 KB
2025-07-11 09:55
Transaction in Own Shares
Medios successfully completes public share buyback offer
English 11.0 KB
2025-06-18 19:16
Transaction in Own Shares
Medios adopts public share buyback offer for up to 1 million shares at a price …
English 11.8 KB
2025-05-27 16:06
Post-Annual General Meeting Information
Medios AG Annual General Meeting 2025: Shareholders approve all proposed resolu…
English 10.1 KB
2025-05-14 07:50
Earnings Release
Medios starts 2025 financial year successfully with significant increase in ear…
English 20.7 KB
2025-05-13 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 10.1 MB
2025-05-12 18:58
Board/Management Information
Medios repositions itself for the next phase of its corporate development
English 12.7 KB
2025-04-14 15:06
Pre-Annual General Meeting Information
Medios AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.05.2025 in…
German 256.2 KB

Automate Your Workflow. Get a real-time feed of all Medios AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medios AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medios AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 van Rietschoten, Constantijn Board Buy None 162,805.82 EUR
2023-06-28 Prußeit, Christoph Board Buy None 39,100.00 EUR
2021-12-09 Miehler, Mi-Young Board Other None 3,550,000.00 EUR
2021-12-09 Prußeit, Christoph Board Other None 1,775,000.00 EUR
2021-12-09 Miehler, Mi-Young Board Other None 700,000.00 EUR
2021-12-09 Prußeit, Christoph Board Other None 350,000.00 EUR

Peer Companies

Company Country Ticker View
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America ANAB
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye ANGEN
ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America ANNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.